These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 3352759)
1. Mechanisms of cross-resistance between radiation and antineoplastic drugs. Ozols RF; Masuda H; Hamilton TC NCI Monogr; 1988; (6):159-65. PubMed ID: 3352759 [TBL] [Abstract][Full Text] [Related]
2. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143 [TBL] [Abstract][Full Text] [Related]
3. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Lau DH; Lewis AD; Ehsan MN; Sikic BI Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140 [TBL] [Abstract][Full Text] [Related]
4. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Louie KG; Behrens BC; Kinsella TJ; Hamilton TC; Grotzinger KR; McKoy WM; Winker MA; Ozols RF Cancer Res; 1985 May; 45(5):2110-5. PubMed ID: 3986765 [TBL] [Abstract][Full Text] [Related]
5. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194 [TBL] [Abstract][Full Text] [Related]
6. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Anderson CP; Reynolds CP Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530 [TBL] [Abstract][Full Text] [Related]
7. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines. Peters RH; Jollow DJ; Stuart RK Cancer Res; 1991 May; 51(10):2536-41. PubMed ID: 2021933 [TBL] [Abstract][Full Text] [Related]
8. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo. Caffrey PB; Zhang Y; Frenkel GD Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503 [TBL] [Abstract][Full Text] [Related]
9. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts. Goddard P; Valenti M; Kelland LR Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451 [TBL] [Abstract][Full Text] [Related]
10. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells. Lai SL; Hwang J; Perng RP; Whang-Peng J Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042 [TBL] [Abstract][Full Text] [Related]
11. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Kramer RA; Greene K; Ahmad S; Vistica DT Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359 [TBL] [Abstract][Full Text] [Related]
12. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051 [TBL] [Abstract][Full Text] [Related]
13. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Schmidt W; Chaney SG Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361 [TBL] [Abstract][Full Text] [Related]
14. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links. Chen G; Zeller WJ Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864 [TBL] [Abstract][Full Text] [Related]
15. Radiation response of drug-resistant variants of a human breast cancer cell line: the effect of glutathione depletion. Lehnert S; Greene D; Batist G Radiat Res; 1990 Nov; 124(2):208-15. PubMed ID: 2247601 [TBL] [Abstract][Full Text] [Related]
16. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322 [TBL] [Abstract][Full Text] [Related]
17. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance. Xu BH; Gupta V; Singh SV Arch Biochem Biophys; 1994 Jan; 308(1):164-70. PubMed ID: 8311448 [TBL] [Abstract][Full Text] [Related]
18. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Yao K; Godwin AK; Ozols RF; Hamilton TC; O'Dwyer PJ Cancer Res; 1993 Aug; 53(16):3662-6. PubMed ID: 8101766 [TBL] [Abstract][Full Text] [Related]
19. Intercellular transfer of drug resistance. Frankfurt OS; Seckinger D; Sugarbaker EV Cancer Res; 1991 Feb; 51(4):1190-5. PubMed ID: 1997161 [TBL] [Abstract][Full Text] [Related]
20. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]